Erratum to: Chordoma: The Quest for Better Treatment Options by unknown
ERRATUM
Erratum to: Chordoma: The Quest for Better
Treatment Options
Christopher R. Heery
To view enhanced content go to www.oncologytherapy-open.com
Received: March 24, 2016 / Published online: April 20, 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
Erratum to: Oncol Ther
DOI 10.1007/s40487-016-0016-0
The author of the above mentioned paper have
noticed a mistake in Table 1 following
publication and wish to make the following
correction.
The reference for the lapatinib study should
be 36 (Stacchiotti S, Tamborini E, Lo Vullo S,
et al. Phase II study on lapatinib in advanced
EGFR-positive chordoma. Ann Oncol.
2013;24:1931–6), and the reference for the
9-nitro-camptothecin study should be 43
(Chugh R, Dunn R, Zalupski MM, et al. Phase
II study of 9-nitro-camptothecin in patients
with advanced chordoma or soft tissue sarcoma.
J Clin Oncol. 2005;23:3597–604).
The corrected Table 1 can be found below.
The online version of the original article can be found
under doi:10.1007/s40487-016-0016-0.
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